Author: James Love

On November 25, 2008, I was invited to give a talk in Vienna, at the meeting of the Chamber of Commerce (the WKO). The event was organized by Eva Lichtenberger, a Green Party MEP. Eva also spoke, and gave a great talk, in German. Her slides were in English, and I’ll add them when I can. The outline of my talk is given below.

Continue Reading →

KEI has filed comments on the EC’s Green Paper on Copyright limitations and exceptions. They are on the web here: https://www.keionline.org/index.php?option=com_content&task=view&id=215

Continue Reading →

UNCTAD head Supachai Panitchpakdi will open up this December 16-19 event in Bangkok. The meeting is funded by the Federal Ministry for Economic Cooperation and Development (BMZ), Germany.

Programme Events

Event: Symposium on Flexibilities in International Intellectual Property Rules and Local Production of Medicines
Date: 16–19 December 2008

Location: Bangkok, Thailand
Venue: Conference Room of Arnoma Hotel
Description:

Continue Reading →

This is an exchange from the ip-health list, that will be updated as the conversation continues, about the impact of the HIF on the generic drug industry developing countries.

—– Original Message —–
From: “James Love”
To: “Ip-health”

Cc: “Thomas Pogge” “Aidan Hollis”
Sent: Wednesday, November 19, 2008 2:15 PM
Subject: impact of the HIF on generic industry in developing countries

Continue Reading →

In an exchange on the i+a listserve, I asked Professor Pogge if the decision to reject open licensing was in part because he was concerned about opposition from certain elements of the pharmaceutical industry. This was his response, shared here with permission:

Continue Reading →

In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about compulsory licensing of patents.

Page 53-54

Continue Reading →

In their recent book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss a number of issues. This is what they say about S.2210 (110th Congress), Senator Sanders’ proposal for the Medical Innovation Prize Fund.

Page 105-106

Medical Innovation Prize Act of 2007

Continue Reading →

In book on the Health Impact Fund,* Aidan Hollis and Thomas Pogge discuss why voluntary licensing of patents is not required.

Page 22

Voluntary Licensing

Continue Reading →

Aidan Hollis and Thomas Pogge discuss Intellectual Property and the HIF.*

Intellectual Property

Continue Reading →

KEI will later issue a more detailed comment on the Health Impact Fund. One of the key issues that will be addressed is the way that Hollis and Pogge propose turning the prize fund proposals that are based upon open licensing of patents into something that reinforces the monopoly supply chain.

We understand that one motivation for doing this was to attract support from some large pharmaceutical companies, and the European governments that protect them.

Continue Reading →